NCT05651022 2026-01-13Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsIndaptus Therapeutics, IncPhase 1/2 Active not recruiting120 enrolled
NCT05431270 2025-01-31Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)Phanes TherapeuticsPhase 1/2 Recruiting40 enrolled